<DOC>
	<DOCNO>NCT00075465</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel epirubicin , work different way stop tumor cell divide stop grow die . Giving one drug may kill tumor cell . PURPOSE : This phase II trial study well give docetaxel together epirubicin first-line therapy work treat patient locally advance metastatic adenocarcinoma ( cancer ) stomach .</brief_summary>
	<brief_title>Docetaxel Epirubicin First-Line Therapy Treating Patients With Locally Advanced Metastatic Adenocarcinoma Stomach</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine objective tumor response rate time tumor progression patient locally advance metastatic adenocarcinoma stomach treat docetaxel epirubicin first-line therapy . Secondary - Determine survival without local relapse overall survival patient treat regimen . - Determine tolerance regimen patient . OUTLINE : This open-label , multicenter study . Patients receive epirubicin IV 30 minute docetaxel IV 1 hour day 1 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 39 patient accrue study .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma stomach Locally advance metastatic disease Measurable disease At least 1 unidimensionally measurable target lesion least 2 cm diameter No known symptomatic brain metastases No bone metastases PATIENT CHARACTERISTICS : Age 18 75 Performance status ECOG 02 Life expectancy At least 3 month Hematopoietic Absolute neutrophil count least 2,000/mm^3 Platelet count great 100,000/mm^3 Hepatic Bilirubin less 2 time normal AST ALT great 2.5 time normal Alkaline phosphatase great 2.5 time normal Renal Creatinine le 1.6 mg/dL OR Creatinine clearance great 60 mL/min Cardiovascular No serious cardiac failure within past 12 month No myocardial infarction within past 12 month No cardiac insufficiency No angina Other Not pregnant nursing Fertile patient must use effective contraception No uncontrolled serious infection No significant brain psychiatric disorder No intolerance cortisone polysorbate 80 No prior malignancy except curatively treat basal cell skin cancer carcinoma situ cervix No illness medical condition would preclude study participation No peripheral neuropathy great grade 2 PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other More 21 day since prior participation another clinical study No concurrent experimental medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
</DOC>